Pomdoctor Unveils Four-Tier Strategy for AI-Driven Healthcare Growth

The company’s roadmap centers on four distinct revenue pillars. The foundation remains its B2C healthcare services, which leverage an internet hospital platform and pharmaceutical supply chain to generate steady income; audited net revenues for this segment reached approximately 399.9 million RMB—roughly 59.04 million USD—in fiscal year 2025. Building upon this, Pomdoctor is introducing AI-enabled chronic disease membership subscriptions. By utilizing wearable devices and remote patient monitoring, the company intends to capture continuous health data to provide personalized interventions for conditions like hypertension and diabetes, aiming to convert one-off consultations into recurring subscription revenue.

Beyond consumer-facing operations, Pomdoctor is expanding its B2B footprint by offering AI-assisted analytics and management tools to hospitals and insurers. The final tier involves the development of a real-world data ecosystem. By aggregating anonymized patient information, the company hopes to support pharmaceutical firms in research and outcome studies. Chairman and CEO Zhenyang Shi emphasized that this strategy does not abandon the firm’s core medical operations but uses them as a springboard for technology-led scaling. Existing partnerships with entities such as Jiangsu Hansoh Pharmaceutical and Xiamen Amoytop Biotech serve as the operational groundwork for these advanced research initiatives.